202 related articles for article (PubMed ID: 36774746)
1. Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms.
Li F; Zheng Z; Chen W; Li D; Zhang H; Zhu Y; Mo Q; Zhao X; Fan Q; Deng F; Han C; Tan W
Drug Resist Updat; 2023 May; 68():100938. PubMed ID: 36774746
[TBL] [Abstract][Full Text] [Related]
2. An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer.
Xylinas E; Hassler MR; Zhuang D; Krzywinski M; Erdem Z; Robinson BD; Elemento O; Clozel T; Shariat SF
Biomolecules; 2016 Sep; 6(3):. PubMed ID: 27598218
[TBL] [Abstract][Full Text] [Related]
3. Rewiring of cisplatin-resistant bladder cancer cells through epigenetic regulation of genes involved in amino acid metabolism.
Yeon A; You S; Kim M; Gupta A; Park MH; Weisenberger DJ; Liang G; Kim J
Theranostics; 2018; 8(16):4520-4534. PubMed ID: 30214636
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapeutics-induced Oct4 expression contributes to drug resistance and tumor recurrence in bladder cancer.
Lu CS; Shieh GS; Wang CT; Su BH; Su YC; Chen YC; Su WC; Wu P; Yang WH; Shiau AL; Wu CL
Oncotarget; 2017 May; 8(19):30844-30858. PubMed ID: 27244887
[TBL] [Abstract][Full Text] [Related]
5. Histone Demethylase KDM7A Regulates Androgen Receptor Activity, and Its Chemical Inhibitor TC-E 5002 Overcomes Cisplatin-Resistance in Bladder Cancer Cells.
Lee KH; Kim BC; Jeong SH; Jeong CW; Ku JH; Kim HH; Kwak C
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32781788
[TBL] [Abstract][Full Text] [Related]
6. Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancer.
Sekino Y; Sakamoto N; Ishikawa A; Honma R; Shigematsu Y; Hayashi T; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
Oncol Rep; 2019 May; 41(5):3111-3118. PubMed ID: 30864720
[TBL] [Abstract][Full Text] [Related]
7. Aberrant DNA methylation of T-cell leukemia, homeobox 3 modulates cisplatin sensitivity in bladder cancer.
Tada Y; Yokomizo A; Shiota M; Tsunoda T; Plass C; Naito S
Int J Oncol; 2011 Sep; 39(3):727-33. PubMed ID: 21617853
[TBL] [Abstract][Full Text] [Related]
8. Targeting HNRNPU to overcome cisplatin resistance in bladder cancer.
Shi ZD; Hao L; Han XX; Wu ZX; Pang K; Dong Y; Qin JX; Wang GY; Zhang XM; Xia T; Liang Q; Zhao Y; Li R; Zhang SQ; Zhang JH; Chen JG; Wang GC; Chen ZS; Han CH
Mol Cancer; 2022 Feb; 21(1):37. PubMed ID: 35130920
[TBL] [Abstract][Full Text] [Related]
9. Cigarette Smoke Containing Acrolein Contributes to Cisplatin Resistance in Human Bladder Cancers through the Regulation of HER2 Pathway or FGFR3 Pathway.
Hong JH; Tong ZJ; Wei TE; Lu YC; Huang CY; Huang CY; Chiang CH; Jaw FS; Cheng HW; Wang HT
Mol Cancer Ther; 2022 Jun; 21(6):1010-1019. PubMed ID: 35312783
[TBL] [Abstract][Full Text] [Related]
10. A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer.
Goodspeed A; Jean A; Costello JC
Eur Urol; 2019 Feb; 75(2):242-250. PubMed ID: 30414698
[TBL] [Abstract][Full Text] [Related]
11. LncRNA MST1P2/miR-133b axis affects the chemoresistance of bladder cancer to cisplatin-based therapy via Sirt1/p53 signaling.
Chen J; Li Y; Li Z; Cao L
J Biochem Mol Toxicol; 2020 Apr; 34(4):e22452. PubMed ID: 32052927
[TBL] [Abstract][Full Text] [Related]
12. A Novel Long Non-Coding RNA KMU15 Promotes Growth and Chemoresistance of Bladder Cancer.
Huang Y; Luan T; Bao X; Fu S; Li N; Li H; Wang H; Li C; Wang J
Clin Lab; 2019 Dec; 65(12):. PubMed ID: 31850704
[TBL] [Abstract][Full Text] [Related]
13.
Wei W; Sun J; Zhang H; Xiao X; Huang C; Wang L; Zhong H; Jiang Y; Zhang X; Jiang G
Cancer Res; 2021 Dec; 81(24):6142-6156. PubMed ID: 34702726
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of cisplatin resistance in bladder cancer.
Drayton RM; Catto JW
Expert Rev Anticancer Ther; 2012 Feb; 12(2):271-81. PubMed ID: 22316374
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy.
Li H; Yu G; Shi R; Lang B; Chen X; Xia D; Xiao H; Guo X; Guan W; Ye Z; Xiao W; Xu H
Mol Cancer; 2014 Jan; 13():8. PubMed ID: 24423412
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells.
Pan J; Li X; Wu W; Xue M; Hou H; Zhai W; Chen W
Cancer Lett; 2016 Nov; 382(1):64-76. PubMed ID: 27591936
[TBL] [Abstract][Full Text] [Related]
17. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer.
Hayden A; Douglas J; Sommerlad M; Andrews L; Gould K; Hussain S; Thomas GJ; Packham G; Crabb SJ
Urol Oncol; 2014 Aug; 32(6):806-14. PubMed ID: 24837013
[TBL] [Abstract][Full Text] [Related]
18. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
Seiler R; Oo HZ; Tortora D; Clausen TM; Wang CK; Kumar G; Pereira MA; Ørum-Madsen MS; Agerbæk MØ; Gustavsson T; Nordmaj MA; Rich JR; Lallous N; Fazli L; Lee SS; Douglas J; Todenhöfer T; Esfandnia S; Battsogt D; Babcook JS; Al-Nakouzi N; Crabb SJ; Moskalev I; Kiss B; Davicioni E; Thalmann GN; Rennie PS; Black PC; Salanti A; Daugaard M
Eur Urol; 2017 Jul; 72(1):142-150. PubMed ID: 28408175
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomic considerations in the treatment of muscle-invasive bladder cancer.
Zuiverloon TC; Theodorescu D
Pharmacogenomics; 2017 Aug; 18(12):1167-1178. PubMed ID: 28745580
[TBL] [Abstract][Full Text] [Related]
20. TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC).
Bunch B; Krishnan N; Greenspan RD; Ramakrishnan S; Attwood K; Yan L; Qi Q; Wang D; Morrison C; Omilian A; Bshara W; Pili R; Trump DL; Johnson C; Woloszynska A
Cell Cycle; 2019 Sep; 18(17):2055-2066. PubMed ID: 31318640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
